This article is more than 5 years old. Information may no longer be current.

Study on regulatory T cells for type 1 diabetes begins

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been enrolled in The Sanford Project: T-Rex Study, which will evaluate the body’s ability to fight type 1 diabetes with cell therapy in adolescents with newly diagnosed disease, according to a press release.

The study is a collaboration between Sanford Health and Caladrius Biosciences Inc.

The effectiveness of cell therapy with expanded regulatory T cells to treat type 1 diabetes will be evaluated throughout the study. Participants’ own regulatory T cells are removed, purified and multiplied, and then returned to the body.

“The enrollment of the first patient in The Sanford Project: T-Rex Study demonstrates Sanford’s commitment to bringing cutting-edge research and next generation treatments to our region,” Kurt Griffin, PhD, MD, director of clinical trials for The Sanford Project, said in a press release. “Leveraging the body’s own natural mechanisms is a particularly appealing approach.”